NASDAQ:PTGX

Protagonist Therapeutics News Headlines

$29.18
+1.16 (+4.14 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.16
$29.62
50-Day Range
$25.22
$31.15
52-Week Range
$9.65
$32.10
Volume1.01 million shs
Average Volume356,811 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56

Headlines

Protagonist Therapeutics (NASDAQ PTGX) News Headlines Today

SourceHeadline
-$0.29 EPS Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter-$0.29 EPS Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter
americanbankingnews.com - May 8 at 9:12 PM
Protagonist Therapeutics (NASDAQ:PTGX) Issues  Earnings ResultsProtagonist Therapeutics (NASDAQ:PTGX) Issues Earnings Results
americanbankingnews.com - May 5 at 4:08 PM
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate UpdateProtagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 7:23 PM
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 4 at 7:23 PM
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical MeetingProtagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting
finance.yahoo.com - April 27 at 8:41 AM
Is PTGX Stock A Buy or Sell?Is PTGX Stock A Buy or Sell?
finance.yahoo.com - April 24 at 7:31 PM
Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 7.4%Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 7.4%
americanbankingnews.com - April 22 at 1:58 PM
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by AnalystsProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 18 at 2:32 AM
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.57Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.57
americanbankingnews.com - April 14 at 1:00 PM
Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth PlansProtagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - April 7 at 2:34 PM
Shout! Acquires North American Rights to ‘The Show,’ Created By Alan Moore, From Protagonist (EXCLUSIVE)Shout! Acquires North American Rights to ‘The Show,’ Created By Alan Moore, From Protagonist (EXCLUSIVE)
msn.com - March 31 at 1:25 PM
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines AgencyProtagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency
finance.yahoo.com - March 22 at 8:29 PM
Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock?Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock?
finance.yahoo.com - March 22 at 9:56 AM
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 12 at 8:00 AM
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 10 at 11:24 PM
Protagonist Therapeutics: Q4 Earnings SnapshotProtagonist Therapeutics: Q4 Earnings Snapshot
finance.yahoo.com - March 10 at 6:10 PM
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdateProtagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - March 10 at 6:10 PM
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial ResultsProtagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 3 at 8:55 AM
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should KnowWill Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know
finance.yahoo.com - March 2 at 2:12 PM
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences ConferenceProtagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:11 AM
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare ConferenceProtagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
finance.yahoo.com - February 16 at 8:27 AM
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their HoldingsProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings
finance.yahoo.com - January 7 at 11:15 AM
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceProtagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:57 AM
MannKind (MNKD) Looks Good: Stock Adds 5.6% in SessionMannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
finance.yahoo.com - December 29 at 1:03 PM
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
finance.yahoo.com - December 16 at 7:45 AM
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesProtagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 15 at 8:17 PM
Is PTGX A Good Stock To Buy Now?Is PTGX A Good Stock To Buy Now?
finance.yahoo.com - December 13 at 12:39 PM
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common StockProtagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 10 at 5:18 PM
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population CategoriesProtagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
finance.yahoo.com - December 7 at 11:34 AM
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia VeraProtagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
finance.yahoo.com - December 6 at 3:30 PM
Protagonists Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia VeraProtagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
finance.yahoo.com - December 2 at 9:24 AM
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
finance.yahoo.com - November 30 at 7:21 AM
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare ConferenceProtagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
finance.yahoo.com - November 25 at 9:24 AM
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare ConferenceProtagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
finance.yahoo.com - November 11 at 6:00 PM
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 4 at 10:02 PM
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate UpdateProtagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 4 at 5:02 PM
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingProtagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
finance.yahoo.com - November 4 at 12:01 PM
Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists programProtagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program
seekingalpha.com - October 30 at 9:34 AM
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with JanssenProtagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
finance.yahoo.com - October 29 at 6:32 PM
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseProtagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - October 28 at 1:58 PM
Protagonist Therapeuticss lead asset an Orphan Drug in Europe for a type of blood cancerProtagonist Therapeutics's lead asset an Orphan Drug in Europe for a type of blood cancer
seekingalpha.com - October 21 at 8:05 AM
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia VeraProtagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
finance.yahoo.com - October 21 at 8:05 AM
Protagonist Therapeutics, Inc. (PGF.SG)Protagonist Therapeutics, Inc. (PGF.SG)
au.finance.yahoo.com - October 11 at 5:05 PM
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment ConferenceProtagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 10 at 9:01 PM
Protagonist Therapeutics to Host PTG-300 Opportunity Update WebinarProtagonist Therapeutics to Host PTG-300 Opportunity Update Webinar
finance.yahoo.com - September 2 at 7:43 PM
Can You Imagine How Protagonist Therapeutics (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM
Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM
Protagonist Therapeutics Inc (NMQ:PTGX) price about to hit new 52-week highProtagonist Therapeutics Inc (NMQ:PTGX) price about to hit new 52-week high
uk.finance.yahoo.com - August 20 at 10:01 AM
Protagonist Appoints Sarah O'Dowd to Board of DirectorsProtagonist Appoints Sarah O'Dowd to Board of Directors
finance.yahoo.com - August 13 at 7:25 PM
Protagonist ramps up construction on Lower South End breweryProtagonist ramps up construction on Lower South End brewery
bizjournals.com - August 7 at 6:56 PM
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.